755 related articles for article (PubMed ID: 25691612)
1. Esophageal and esophagogastric junction cancers, version 1.2015.
Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Besh S; Chao J; Das P; Denlinger C; Fanta P; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Jasperson K; Keswani RN; Kleinberg LR; Korn WM; Leong S; Lockhart AC; Mulcahy MF; Orringer MB; Posey JA; Poultsides GA; Sasson AR; Scott WJ; Strong VE; Varghese TK; Washington MK; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H;
J Natl Compr Canc Netw; 2015 Feb; 13(2):194-227. PubMed ID: 25691612
[TBL] [Abstract][Full Text] [Related]
2. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Ajani JA; D'Amico TA; Bentrem DJ; Chao J; Corvera C; Das P; Denlinger CS; Enzinger PC; Fanta P; Farjah F; Gerdes H; Gibson M; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Johung KL; Keswani RN; Kleinberg LR; Leong S; Ly QP; Matkowskyj KA; McNamara M; Mulcahy MF; Paluri RK; Park H; Perry KA; Pimiento J; Poultsides GA; Roses R; Strong VE; Wiesner G; Willett CG; Wright CD; McMillian NR; Pluchino LA
J Natl Compr Canc Netw; 2019 Jul; 17(7):855-883. PubMed ID: 31319389
[TBL] [Abstract][Full Text] [Related]
3. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Ajani JA; D'Amico TA; Bentrem DJ; Cooke D; Corvera C; Das P; Enzinger PC; Enzler T; Farjah F; Gerdes H; Gibson M; Grierson P; Hofstetter WL; Ilson DH; Jalal S; Keswani RN; Kim S; Kleinberg LR; Klempner S; Lacy J; Licciardi F; Ly QP; Matkowskyj KA; McNamara M; Miller A; Mukherjee S; Mulcahy MF; Outlaw D; Perry KA; Pimiento J; Poultsides GA; Reznik S; Roses RE; Strong VE; Su S; Wang HL; Wiesner G; Willett CG; Yakoub D; Yoon H; McMillian NR; Pluchino LA
J Natl Compr Canc Netw; 2023 Apr; 21(4):393-422. PubMed ID: 37015332
[TBL] [Abstract][Full Text] [Related]
4. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
[TBL] [Abstract][Full Text] [Related]
5. Third international conference of the European Union Network of Excellence on gastric and esophagogastric junction cancer, Cologne, Germany, June 2012.
Moenig SP; Meyer HJ; Allum WH; De Manzoni G; Garofalo A; Baltin CT; Fetzner UK; Hoelscher AH
Gastric Cancer; 2015 Jan; 18(1):193-9. PubMed ID: 24522716
[TBL] [Abstract][Full Text] [Related]
6. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
Moehler M; Baltin CT; Ebert M; Fischbach W; Gockel I; Grenacher L; Hölscher AH; Lordick F; Malfertheiner P; Messmann H; Meyer HJ; Palmqvist A; Röcken C; Schuhmacher C; Stahl M; Stuschke M; Vieth M; Wittekind C; Wagner D; Mönig SP
Gastric Cancer; 2015 Jul; 18(3):550-63. PubMed ID: 25192931
[TBL] [Abstract][Full Text] [Related]
7. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?
Al-Batran SE; Lorenzen S
Hematol Oncol Clin North Am; 2017 Jun; 31(3):441-452. PubMed ID: 28501086
[TBL] [Abstract][Full Text] [Related]
8. Treatment approaches to esophagogastric junction tumors.
Kurokawa Y; Sasako M; Doki Y
Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
[TBL] [Abstract][Full Text] [Related]
9. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
[TBL] [Abstract][Full Text] [Related]
10. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
[TBL] [Abstract][Full Text] [Related]
11. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
Sandler S
Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
[TBL] [Abstract][Full Text] [Related]
12. [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences].
Gockel I; Lordick F; Lyros O; Kreuser N; Hölscher AH; Wittekind C
Chirurg; 2020 Jan; 91(1):41-50. PubMed ID: 31372677
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic approaches to gastroesophageal junction adenocarcinomas.
Blom RL; Bogush T; Brücher BL; Chang AC; Davydov M; Dudko E; Leong T; Polotsky B; Swanson PE; van Rossum PS; Ruurda JP; Sagaert X; Tjulandin S; Schraepen MC; Sosef MN; van Hillegersberg R
Ann N Y Acad Sci; 2014 Sep; 1325():197-210. PubMed ID: 25266026
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options?
Gronnier C; Piessen G; Mariette C
J Visc Surg; 2012 Feb; 149(1):e23-33. PubMed ID: 22341763
[TBL] [Abstract][Full Text] [Related]
15. EGJ and esophageal cancers: choosing induction therapy so as to err on the side of overtreatment rather than undertreatment when staging is imperfect.
Meyers BF; Samson PP
Oncology (Williston Park); 2014 Jun; 28(6):512, 519-20. PubMed ID: 25134326
[No Abstract] [Full Text] [Related]
16. Cancer of the esophagogastric junction.
Stein HJ; Feith M; Siewert JR
Surg Oncol; 2000 Jul; 9(1):35-41. PubMed ID: 11525305
[TBL] [Abstract][Full Text] [Related]
17. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Fernandez E; Cacheux W; Frossard JL; Koessler T; Abou M; Moniez M; Huber O; Puppa G; Roth A
Dig Liver Dis; 2017 May; 49(5):552-556. PubMed ID: 28179095
[TBL] [Abstract][Full Text] [Related]
18. [Multimodality therapy for adenocarcinoma of the esophagogastric junction].
He J; Huang JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Sep; 15(9):877-80. PubMed ID: 22990915
[TBL] [Abstract][Full Text] [Related]
19. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West.
Wilke H; Lordick F; Meyer HJ; Stahl M
Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction.
Pera M
Recent Results Cancer Res; 2000; 155():1-14. PubMed ID: 10693234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
